Therapy Options

Adeno-associated virus (AAV) vectors can deliver a functional copy of a nuclear gene to target cells. For MRPL39, an AAV carrying a corrected MRPL39 coding sequence could restore mitoribosomal assembly and downstream OXPHOS protein production. AAV gene therapy has achieved regulatory approval for other metabolic diseases (including spinal muscular atrophy and aromatic L-amino acid decarboxylase deficiency), establishing the platform's feasibility in neurometabolic conditions.

Key unknowns for MRPL39-directed AAV: optimal serotype for brain and heart tropism, dosing, timing, and whether early intervention before significant neurological injury preserves meaningful function. Patient-derived cellular models would be essential for preclinical validation.

Antisense oligonucleotides (ASOs) are short synthetic nucleic acids that bind to pre-mRNA and redirect splicing. For Iris's maternal variant — the deep intronic c.589-924G>A — this mutation creates a cryptic splice site that causes pseudoexon inclusion and near-complete loss of correctly-spliced MRPL39 transcript. A splice-blocking ASO targeting the pseudoexon could theoretically suppress aberrant inclusion and restore normal splicing.

This strategy has direct regulatory precedent: nusinersen (Spinraza) for SMA is an ASO that redirects SMN2 splicing and is now a standard of care. While RNA-sequencing and mechanistic validation specific to MRPL39 would be required, the maternal allele's splice defect is a compelling and drug-like target.

Before any therapy can be tested in Iris, researchers need disease models. Patient-derived fibroblasts from Iris could be used immediately for biochemical and functional studies — measuring MRPL39 expression, mitoribosomal assembly, and OXPHOS activity. These cells could also serve as the readout system for testing splice-correction ASOs or small molecule approaches.

Induced pluripotent stem cell (iPSC) derivation would enable cardiomyocyte and neuron models — the cell types most affected in Iris — for more disease-relevant preclinical rescue studies and therapeutic endpoint development.

Fewer than 50 patients with MRPL39 disease have been reported in the literature. Natural history data is sparse. Iris's case — which is unusually deeply phenotyped with serial EEG, MRI/MRS, cardiac imaging, nutritional data, and RNA sequencing — represents an extraordinary data point for the field.

Inclusion in natural history registries for Leigh Syndrome or mitochondrial translation disorders would help define the clinical spectrum of MRPL39 disease, identify biomarkers, and provide the historical control data needed to design and power future therapeutic trials.

While no disease-modifying therapy exists, Iris receives a comprehensive supportive care regimen. Mitochondrial "cocktail" supplements — including CoQ10, riboflavin, thiamine, L-carnitine, and antioxidants — are standard supportive care in Leigh Syndrome, though evidence for disease modification is limited. Their primary goal is to support residual mitochondrial function and reduce oxidative stress.

Cardiac management with beta-blockade and careful fluid management addresses her hypertrophic cardiomyopathy. Autonomic intervention — including botulinum toxin to reduce defecation-triggered vagal events — has been associated with meaningful clinical improvement in her respiratory stability.